Results 81 to 90 of about 10,389 (214)

Modeling Parkinson’s Disease in Drosophila: What Have We Learned for Dominant Traits?

open access: yesFrontiers in Neurology, 2018
Parkinson’s disease (PD) is recognized as the second most common neurodegenerative disorder after Alzheimer’s disease. Unfortunately, there is no cure or proven disease modifying therapy for PD.
Yulan Xiong, Jianzhong Yu
doaj   +1 more source

Metabolic Structure: A Paradigm Revisited in Light of the Fundamental Parameters of Living Systems

open access: yesBioEssays, Volume 48, Issue 10, October 2026.
Metabolism is redefined as a dynamic thermodynamic field shaped by six fundamental parameters (time, water, entropy, quantum effects, space, and electrostatics) rather than fixed genetic architecture. Case studies from enzyme kinetics to cancer cell differentiation show metabolic states, not structure alone, determine flux and control, and can be ...
Jacques Fantini
wiley   +1 more source

N-Guanidino Derivatives of 1,5-Dideoxy-1,5-imino-d-xylitol are Potent, Selective, and Stable Inhibitors of β-Glucocerebrosidase [PDF]

open access: yes, 2017
A series of lipidated guanidino and urea derivatives of 1,5-dideoxy-1,5-imino-d-xylitol were prepared from d-xylose using a concise synthetic protocol.
Afd Chemical Biology and Drug Discovery   +25 more
core   +1 more source

Small Molecule Therapeutic Approaches With a Greater Focus on Hearing Loss: A Review

open access: yesHealth Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aims Hearing loss (HL) is one of the most common sensory impairments worldwide and has substantial effects on quality of life and daily functioning. Although cochlear implants and hearing aids have markedly improved the management of hearing impairment, these devices do not directly address the underlying pathogenic mechanisms ...
Maryam Naghinejad   +5 more
wiley   +1 more source

Association Between Glucocerebrosidase Mutations and Parkinson's Disease in Ireland

open access: yesFrontiers in Neurology, 2020
Multiple studies implicate heterozygous GBA mutations as a major genetic risk factor for Parkinson's disease (PD); however, the frequency of mutations has never been examined in PD patients from the Irish population.
Diana A. Olszewska   +15 more
doaj   +1 more source

Human biomarker navigator

open access: yesiMeta, Volume 5, Issue 5, October 2026.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li   +29 more
wiley   +1 more source

Glucocerebrosidase Cleaves a Linkage within Glucosylceramide, a Normal Intermediate in Glycolipid Metabolism

open access: yes, 2013
Glucocerebrosidase Cleaves a Linkage within Glucosylceramide, a Normal Intermediate in Glycolipid ...
Ernest Beutler (5254)
core   +1 more source

Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review

open access: yesMovement Disorders Clinical Practice, Volume 13, Issue 10, Page 2379-2394, October 2026.
Abstract Background Parkinson's disease (PD) is a worldwide, complex neurodegenerative disorder influenced by both genetic and environmental factors. Around 15–20% of PD cases are linked to genetic mutations, providing insights into the disease's pathogenesis.
Chiara Meneghini   +5 more
wiley   +1 more source

Glucocerebrosidase mutations disrupt the lysosome and now the mitochondria

open access: yes, 2023
β-Glucocerebrosidase (GCase) mutations lead to glucosylceramide build-up in the lysosome, impacting α-synuclein aggregation and autophagy. Recently, Baden and colleagues found GCase in mitochondria, supporting mitochondrial complex I function and energy ...
Outeiro, Tiago Fleming   +2 more
core   +1 more source

Applying a Pareto‐Based Efficiency Frontier to Inform Value‐Based Pricing for Gaucher Disease Therapies in Brazil

open access: yesPharmacoepidemiology and Drug Safety, Volume 35, Issue 10, October 2026.
ABSTRACT Purpose Gaucher disease (GD) requires lifelong high‐cost treatment within the Brazilian Unified Health System (SUS). In Brazil, treatment eligibility and monitoring are defined by Clinical Protocol and Therapeutic Guidelines (PCDT), while pharmaceutical prices are regulated by the Drug Market Regulation Chamber (CMED).
Marcus Carvalho Borin   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy